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Background: Plasmablastic lymphoma (PBL) is a rare subtype of non-Hodgkin’s lymphoma. Characterized
by its aggressive nature and plasmacytic differentiation, PBL remains a therapeutic and diagnostic challenge;
it generally has a poor prognosis with very few long-term survivors and most patients dying within 2 years
from initial presentation.
PBL has been reported in several other countries; however, there have been no reported cases from Saudi
Arabia. Here, we report 8 cases of PBL depicting the clinical presentation, immunocompetency,
immunphenotypic characterization, diagnostic challenges and treatment outcome.
Methods: The medical records were reviewed for clinical presentation, staging, laboratory data, radiological
studies, treatments, and outcomes. A broad immunohistochemical panel consisting of CD45, CD3, CD20,
CD79a, Pax5, CD38, CD138, MUM1, EMA, Kappa, Lambda, CD 56, CD30, Bcl-2, Bcl-6, Alk-1, Ki-67,
EBV-LMP-1, and HHV8 was performed.
Results: The tumors predominantly exhibited immunoblastic/plasmablastic or plasmacytic morphologic
features and had a plasma cell–like immunophenotype. All cases were immunoreactive for CD38, CD138
and MUM1 confirming plasma cell differentiation of the tumor cells. CD20 was negative for all cases; whereas CD79a
and Pax5 were weakly positive in 2cases. All 8 cases were EBV-LMP-1/EBER-1 negative, and 1 case was HHV8 positive.
Similar to previously published studies, PBL in Saudi Arabia is characterized by male predominance (6/8), median age
51.5 years (mean age 46 years), associated with early dissemination, poor response to therapy, and limited survival
(average survival time, 6.4 months, median overall survival 5.5 months). However, it does have some unique features.
It occurs more commonly in immunocompetent persons (6/8, 75 %), is not associated with EBV infection (0/8), and
nodal involvement (either primary or secondary) is common among patients (6/8).
In addition, extra-oral sites are more common than oral/nasal cavities (7/8) and the c-myc gene is not
common (1/8, 12.5 %).
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Conclusion: It appears that PBL is heterogeneous in terms of clinical presentation and morphology. PBL is
a therapeutic challenge with a clinical course that is characterized by its high rate of relapse and death.
To date, treatment responses are usually partial and temporary. Therapies that are more intensive than CHOP
do not seem to prolong survival. Further research is needed to understand the biology and molecular
pathogenesis of PBL in order to improve therapies.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1465801416161912
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Plasmablastic lymphoma (PBL) is a rare aggressive subtype
of non-Hodgkin’s lymphoma (NHL). Initially described in
1997, it occurs predominantly in HIV infected individuals
and shows a predilection for the oral cavity [1–3].
Recently, dual infection with Epstein-Barr virus (EBV)
and human herpesvirus 8 (HHV8) has been demon-
strated in PBL. A number of cases have been reported in
extra-oral sites, including the maxillary sinus, nasophar-
ynx, stomach, small bowel, anus, lung, skin, soft tissues,
heart and the spermatic cord [4].
PBL usually develops in middle-aged adults, with the
age at onset ranging from 35 to 55 years [5], but it can
occur in the pediatric age group [6, 7].
The clinical course of PBL is characteristically ag-
gressive; the prognosis is poor, with death occurring
between 1 and 24 months after diagnosis (average
survival time, 6 months) [8]. Spontaneous regression
has been reported with highly active antiretroviral
therapy (HAART) [9–11] with a prolonged median
overall survival (OS) time of 15 months [12] and dur-
able responses to chemotherapy [13–16].
The clinical and histopathological features are fre-
quently ambiguous, rendering the correct diagnosis quite
difficult in the absence of an exhaustive integration of
clinical, morphological, phenotypic and molecular fea-
tures. The diagnosis of such neoplasms can be even more
challenging in the setting of extra-oral localizations and in
immunocompetent patients.
Here, we report 8 cases of PBL from Saudi Arabia
depicting clinical presentation, immunocometency, immu-
nophenotypic characterization and treatment outcome.Methods
Study population
The study cohort comprised of 8 patients whose path-
ology slides were reviewed at Prince Sultan Military
Medical City (PSMMC), Saudi Arabia between 2006 and
2014. All biopsies were obtained at diagnosis; all cases
were reviewed for clinical data, primary site, staging,
relevant laboratory data, radiological studies, treatmentand outcome. This study was approved by the Ethical
and Research Committee of the PSMMC.Morphological features
Hematoxylin-eosin (H&E) sections were reviewed, and
morphological findings were summarized. The initial
histological diagnosis was based on H&E staining and
immunophenotyping results.Immunophenotyping
Immunohistochemical studies were performed on
formalin-fixed paraffin-embedded tissue using an au-
tomated immunostainer and a broad panel of anti-
bodies, including LCA, CD3, CD20, CD79a, PAX5,
CD 56, CD10, Ki-67, HHV8, ALK-1, cyclin D1, CD38,
CD138, Kappa and Lambda, CD30, bcl-2, bcl-6,
MUM-1, EMA, HHV8 and EBV-LMP-1 according to
the manufacturer’s instructions. Some markers were not
assessed in all cases due to the limited amount of tissue.In situ hybridization for EBV
In situ hybridization (ISH) for EBV-encoded RNA
(EBER-1) was performed on formalin-fixed paraffin-
embedded tissue sections for 6 of the 8 cases with suffi-
cient tissue using ISH according to the manufacturer’s
instructions with the appropriate positive and negative
controls. All cases were assessed for EBV-encoded
LMP1 by immunohistochemistry (IHC).Cytogenetic analysis
Conventional chromosome analysis was performed on
the other two cases by the standard cytogenetic protocols
for neoplastic studies [17]. Fluorescent in situ
hybridization (FISH) analysis was performed on all pa-
tients with the MYC probe (LSI MYC Dual Color, Break-
Apart Rearrangement probe) to investigate the presence
of MYC gene rearrangement. The FISH procedure was
carried out on bone marrow aspirates (3 cases) and
formalin-fixed, paraffin-embedded tissue sections (all
cases), following the manufacturer’s guidelines.
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Clinicopathological variables were dichotomized to
facilitate analysis and are presented using descriptive
methods. Complete remission (CR) is defined as the
disappearance of all clinical evidence of disease and
the normalization of clinical symptoms, laboratory values,
CT scans and a bone marrow (BM) biopsy (if initially
involved) after treatment. The overall survival (OS) is
defined as the time (in months) from diagnosis to the date
of death from any cause or last follow-up.
Results
Clinical features
The clinical features of the patients are summarized in
Table 1.
Of the 8 cases, 6 were males and 2 were females with an
age range of 20–59 years (median age 51.5 years). Seven
patients were categorized intermediate- to high-risk IPI
and one case was low risk. Two of the patients (25 % -
cases 6 and 8) were positive for HIV, and 1 patient was
infected with human herpes virus 8 (HHV8 - case 2).
The primary involved locations were lymph nodes, the
parotid gland, skin, nasopharynx, ovary, maxillary bone
and iliac fossa. Seven cases presented with disseminatedTable 1 Clinical features of PBL cases
Patient # Case 1 Case 2 Case 3 Case
Age 59 58 52 20
Gender Female Male Male Mal







No Yes Yes Yes
Other Organs
involved
CNS Spleen Lungs CNS
Multiple bone Liver Live
Lungs
B-symptoms Yes Yes No Yes
HIV status ─ ─ ─ ─
BM involvement + ─ + +
Stage IV IV IV IV
Lytic lesions Yes No No No
M protein IgG ─ IgM
CSF cytology ─ ─ ─ ─




Partial No Partial No
Outcome Died of
disease





12 3 9 1
ND Not done, N/A Not applicabledisease stage IV, multifocal nodal involvement (6 cases),
and an extra-nodal disease involving the liver, spleen,
soft tissue and CNS.
Of the 8 patients, four had some clinical features of
plasma cell myeloma, which includes monoclonal serum
immunoglobulin spikes and/or lytic lesion; however, all
four patients had normal serum calcium, blood urea ni-
trogen, and creatinine. Lytic bone lesions were observed
in three patients. Two patients had monoclonal serum
immunoglobulin spikes (case 1 and case 7). The mono-
clonal immunoglobulins were IgG and IgA. The patient
with IgG had multiple lytic bone lesions determined by
computed tomography (CT) scans. The other patient
had a monoclonal IgA spike, but there was no evidence
of lytic bone lesions.
Three of our PBL cases were treated by CHOH-R and
had an average OS of 11 months. Two of our cases
received a combination of chemotherapeutic drugs in-
cluding etoposide, methylprednisolone, high-dose cytara-
bine and cisplatin, (ESHAP) and had an average OS of
5 months. One of the cases (case 4) was treated by bor-
tezomib with dexamethasone and died after 1 month of
final diagnosis due to disease progression. Two of the
patients received palliative chemotherapy due to the4 Case 5 Case 6 Case 7 Case 8
33 43 52 51
e Male Male Female Male
/LNs Neck masses
/LNs
LNs Ovary Maxillary bone/
tissue
Yes Yes Yes No
Spleen Spleen GIT No
r Liver Liver
Lungs
Yes Yes Yes No
─ + ─ +
─ + + ND
IV IV IV I
No Yes Yes No
─ ─ ─ ─
─ ─ ─ ─
ezomib ESHAP Palliative Palliative CHOP-R
amethasone
Partial N/A N/A Partial







7 2 4 13
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3 months. Intrathecal chemotherapy was administered




All PBL cases showed morphologic features of diffuse
proliferation of predominantly large lymphoid cells with
plasmablastic, immunoblastic or plasmacytic morph-
ology. The number of the more mature plasma cells
ranged from minimal to moderate in the various cases.
The neoplastic cells had round nuclei, vesicular chroma-
tin, smooth nuclear contours, prominent central/periph-
eral/or multiple small nucleoli, variably eccentrically
located nuclei, and abundant cytoplasm (Fig. 1).
The bone marrow was diffusely infiltrated by large
cells in 5 cases with morphological features similar to
tissue sections. All CSF cytology was negative for malig-
nant cells even though radiological work up showed evi-
dence of CNS involvement in 2 cases.
Immunophenotype
The IHC characteristics are summarized in Table 2. The
tumor cells of PBL exhibit features of terminally differ-
entiated B-cells and express antigens in a pattern similarFig. 1 a–o: Histomorphologic features and phenotypic profile of PBL cases
showing plasmablastic/immunoblastic morphology (a), cases 2 or plasmacy
(c) and is strongly positive for CD138 (d), case 1. e Staining with Ki-67 show
positivity in neoplastic cells by immunohistological stain, case 4 and by ISH
hybridization (h) and positivity to HHV8 by immunohistological stain (i) res
shows strong and diffuse positivity in case 4 (k). l & m The tumor cells are
n & o Case 2 shows strong positivity for CD30 staining (n) and negative foto plasma cells. All cases were positive for CD38,
CD138, and MUM1; variably positive for CD45, CD79a,
Pax5, EMA and CD30. All cases were nonreactive to
CD20, and one case (case 1) was positive for CD56. The
proliferation index showed a high range from 70 to 90 %
(the average was 76 %). EBV infection was negative in all
8 cases examined (EBV positivity was determined on the
basis of EBER-1 in situ hybridization (6/8) and immuno-
histochemical staining of EBV-LMP1 (8/8); whereas
HHV 8 was positive in one case (case 2). Only one case
was positive for C-MYC gene by IHC (Fig. 1).Cytogenetic analysis
Because conventional chromosome analysis only was ob-
tainable in two cases, correlation with conventional
karyotypic analysis was not possible.
All but one case (case 7) showed no presence of MYC
translation after going through FISH analysis Fig. 2. One
case (case 1), showed complex cytogenetic changes that
are more commonly observed in plasma cell myeloma
with extra copies of chromosomes 8, 11, and 17 (40 %)
indicating the presence of a hyperploid tumoral clone
and was reported as nuc ish (TP53 × 3)[80/200]/
(CCND1) × 3 (IGH) × 2 [80/200]/(5′MYC, 3′MYC,5′
MYC con 3′MYC) × 3[80/200].. a & b H&E, PBL consists of a population of large lymphoid cells
tic morphology (b), case 7. c & d PBL typically lacks CD20 expression
s a high proliferation rate, case 7. f & g Lambda, light chain shows
respectively, case 2. h & i Tumor cells show negativity to EBER in situ
pectively, case 2. j and k PBL shows negativity to CD45, case 8 whereas
positive for EMA (l), case 4 and positive for MUM-1 stain in case 7 (m).
r ALK-1 immunohistochemical staining (o)
Table 2 The immunohistochemical characteristics of the PBL cases




EBV- LMP1 HHV8 CD10 BCL2
BCL6
Ki-67
Case 1 ─ ─ ─ ─ ─ + + + ─ + Lambda ─ ─ ─ ─ ─ >90 %
Case 2 + ─ ─ ─ ─ + + + + ─ Lambda ─ ─ ─ + ─ >80 %
Case 3 ─ ─ ─ ─ ─ + + + ─ ─ ND ─ ─ ─ ─ ─ >80 %
Case 4 + ─ ─ +/─ ─ + + + + ─ Lambda ─ ─ ─ ─ ─ >80 %
Case 5 +/─ ─ ─ ─ ─ + + + + ─ ND ─ ─ ─ ─ ─ >70 %
Case 6 ─ ─ +/─ ─ ─ + + + ─ ─ Lambda ─ ─ ─ ─ ─ >70 %
Case 7 ─ ─ +/─ +/─ ─ + + + ─ ─ Kappa ─ ─ ─ ─ ─ >70 %
Case 8 ─ ─ ─ ─ ─ + + + + ─ Kappa ─ ─ ─ ─ ─ >70 %
ND Not done
+/−: Weak positive, +: Positive, −: Negative
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PBL is a rare aggressive B-cell NHL that is often related
to EBV infection; it accounts for 2.6 % of all AIDS-
related lymphomas with overall survival rates between 6
and 12 months [18, 19]. The available pathological, im-
munohistochemical, molecular, and genetic data suggests
that plasmablastic lymphoma arises from post-germinal
centre, terminally differentiated, activated B-cells that
are in transition from immunoblasts to plasma cells [20].
Array comparative genomic hybridization (involving 16
cases of PBLs) demonstrates that despite the high degree
of immunophenotypical similarity between PBL and
plasma cell myeloma (PCM) [21], the genomic aberra-
tion pattern of PBL is more similar to DLBCL than to
PCM [22].
Similar to previously published studies [3], our pa-
tients are characterized by male predominance (6/8).
Though the reason for this observation is not clear, it
may be due, in part, to the over-representation of HIV
infection in men compared to women in developedFig. 2 FISH study performed on interphase cells using probes to the
MYC (red signal) and IGH (green signal) loci demonstrates that the
neoplastic cells contain a reciprocal translocation between the MYC
and IGH loci (yellow signals), case 7countries [23]. Another contributing factor could be
the fact that a number of cancer-related genes, known
as cancer/testis antigens (CTAs) that are located on
the X-chromosome (MAGEA1, SSX1, SSX4, and
CTAG1/2) [24–26], are highly upregulated in PBL,
which mainly affect male individuals [27]. However,
CTAs can be aberrantly expressed in different types
of cancer [28, 29].
In PBL, extranodal involvement occurs much more
frequently than nodal involvement with a predilection
for the oral/nasal cavity [12]. In this study, nodal in-
volvement (either primary or secondary) is common
among patients. (6/8) However, extra-oral sites were
more common than oral sites. These differences may be
attributed to the small sample size.
EBV has been found to be associated with AIDS re-
lated lymphomas and is thought to play a key role in its
pathogenesis. In one study, there was a 70 % association
between PBL and EBV [12, 30–32]. As reported by
Delecluse et al., [1], 9 of 15 cases were found to be associ-
ated with EBV using ISH; of these 9 cases, 5 demonstrated
expression of latent membrane proteins (LMP-1). In an-
other study of oral cavity PBL, 10 of 12 cases tested posi-
tive using EBV-EBER in situ hybridization, but none of
the 12 were reactive for EBV-L MP-1 [13, 33]. In our
study, EBV-LMP-1 also failed to react in all 8 cases exam-
ined. Although this technique is less sensitive than ISH,
our study failed to detect the presence of EBV in all 8
cases. Six cases tested by EBER-1, were non- reactive for
EBV, thus conflicting with previous reports that demon-
strated a strong association and a role of EBV infection in
tumorigenesis in a portion of PBL cases [1, 12, 33]. How-
ever, this does not hold true for all cases of PBL, as dem-
onstrated in our study and other reported cases of EBV-
negative PBLs [1, 33–35]. The significant value of
association between EBV expression and PBL cases is
unclear. Some studies have shown a better outcome in
immunocompetent patients with PBL, while others have
shown that EBV expression is not associated with the
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results (though the sample size is small) shows that EBV
infection is not the sole cause of the disease.
Although PBL was originally associated with AIDS, an
increasing number of reports has described cases arising
in immunocompetent individuals [2, 36, 39]. It is cur-
rently unclear if HIV status alone confers a better prog-
nosis in patients with PBL. In a recent review of
literature, patients with PBL and HIV infection were
found to have an OS of 14 months compared to
9 months in HIV-negative patients [36]. A review of 112
HIV positive patients with PBL showed a median overall
survival (OS) of 15 months and a 3-year OS rate of 25 %
[12], compared to a review of 76 HIV-negative PBL
patients that showed a median OS of 9 months with
a 2-year OS rate of 10 % [40].
The reasons for the better outcome are unclear, but a
potential explanation for this finding is that the use of
highly active antiretroviral therapy (HAART) may re-
store immune surveillance to combat the tumor more
efficiently. However, other studies do not support this
result [27, 36, 41].
In our PBL study, 2 male patients of the 8 cases (25 %)
were positive for HIV and had an average OS of
6.5 months which is similar to HIV negative patients
(6 months). This may be attributed to the fact that our
patients were not on HAART at presentation and the
small sample size.
PBL is associated with rearrangements in the c- MYC
gene in more than 40 % of cases [42, 43]. Valera and
colleagues reported c- MYC rearrangement in 50 % of
the cases reviewed and noted that EBV positive patients
are more likely to have the c- MYC abnormality and c-
myc rearrangement occurs less frequently in EBV
negative patients [44]. The presence of a MYC/IgH
rearrangement is associated with a worse overall sur-
vival [38, 42, 44]. In our study, the c- MYC gene is
not common among our PBL series as FISH analysis
failed to detect the presence of MYC translocation in
7 patients and only one case (case 7) was positive for
MYC translocation. The discrepancy between our re-
sults and those previously reported may be due to a
small sample size, ethnic characteristics, or molecular
characteristics of this lymphoma in our population.
In addition, all cases were EBV negative and may
serve as a contributing factor since c-myc rearrange-
ment occurs less frequently in EBV negative patients
as reported by previous studies [44].
Since there is no standard chemotherapy protocol
for treatment of this type of lymphoma, 3 of our PBL
cases were treated by anthracycline based protocols
(Cyclophosphamide, Adriamycin, Vincristine, Prednis-
olone and Rituximab or CHOP-R), and 2 cases re-
ceived a regimen combination of chemotherapeuticdrugs including etoposide, methylprednisolone (solu-
medrol), high-dose cytarabine (ara-C) and cisplatin
(ESHAP). Both of these regimens were combined with
radiotherapy when indicated. Two cases received
palliative chemotherapy (due to the patients’ clinical
condition), and one case was treated by bortezomib
which is a proteasome inhibitor and a cornerstone in
myelomas therapy and relapsed or refractory mantle
cell lymphoma [45]. Although CD20 expression was
nonreactive in all cases, we used anti-CD20 monoclo-
nal antibody rituximab with CHOP protocol, though
its use in such cases are of uncertain utility [46].
Among the 6 patients who received chemotherapeutic
regimens, none of them (0 %) achieved complete remis-
sion (CR), 4 (66 %) had a partial response (PR) and 2
(33 %) did not respond (NR) or progress. Since the sam-
ple size is small, we cannot give conclusive results, but it
appears that the more intensive regimen ESHAP does
not show a survival advantage when compared to the
less intensive CHOP-R regimen. The treatment re-
sponses were partial and temporary in both regimens
which is similar to the results that have been published
in several past studies [38, 47]. Patients with PBL that
were not treated with chemotherapy invariably died with
a median survival of 3 months [36]. Similarly, 2 of our
patients received palliative therapy and died with a me-
dian survival of 3 months. The patient (case 4) that was
treated with bortezomib, a proteasome inhibitor with
dexamethasone, was without improvement and died
after one month of final diagnosis due to disease
progression.
Generally, PBL has a poor prognosis with very few
long term survivors and most patients dying within
2 years from initial presentation [48]. The survival out-
comes in this study are similar to those published in
other studies [12, 49]. The median OS was 5.5 months
(average survival time 6.4 months) from diagnosis but
varied considerably (range, 1 to 13 months). The average
survival time reported by Delecluse et al. [1], was a few
months, and half of the 16 patients with available follow
up, died within 12 months of diagnosis. In one series of
13 patients, all died within 34 months with a median
survival of 7 months. [11] Of the 90 cases in literature
that mention survival data, almost half (47 %) died
within 1 year of diagnosis; others report a very short sur-
vival [11, 35].
More recent reports have reported improved survival
in HIV infected PBLs when treated with both HAART
and appropriate chemotherapy. This is similar to out-
comes of HIV infected patients with other NHLs [7, 12].
However, the outcome presented here is inferior to that
recently reported [7, 12, 16]. The difference may be
attributed to several factors, including ethnic and
molecular differences. Most of the cases (7/8, 95 %)
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tive which are associated with poor prognosis [21, 26].
Because the clinical and histopathological features
are usually ambiguous, PBL remains a diagnostic chal-
lenge. Rendering the correct diagnosis can be quite
difficult in the absence of an exhaustive integration of
clinical, morphological, phenotypic and molecular fea-
tures. The diagnosis of such neoplasms can be even
more challenging in the setting of extra-oral localiza-
tions and in immunocompetent patients. The differen-
tial diagnosis with the activated B-cell-like (ABC-like)
subgroup of DLBCL and PCM with plasmablastic morph-
ology is still a common problem due to the lack of a
distinctive phenotype. The differential diagnosis includes
immunoblastic DLBCL and other lymphoid neoplasms
with plasmacytic features such as ALK-positive DLBCL,
primary effusion lymphoma (PEL), BL with plasmacytoid
differentiation and plasmablastic plasmacytoma/myeloma
(Table 3). Immunoblastic DLBCL and BL can be excluded
on the basis of the characteristics CD20 and LCA positiv-
ity in combination with negative markers of plasma cells,
such as CD138 [1, 8]. PBL is distinguished from ALK-
positive DLBCL by its lack of expression of the ALK
protein, and the absence of HHV8 co-infection distin-
guishes PBL from PEL which usually manifests as pleural
or pericardial effusion and rarely associates with lymph-
adenopathy or mass. PBL is also variably positive for
CD30, epithelial and endothelial markers such EMA and
CD31, posing some problems in differential diagnosis with
poorly differentiated solid tumors [50].Table 3 Differentiating PBL from other Neoplasms by Immunophen











Immunocompetency +/− ++ +++ +/






LCA +/− + + +/
B-Cell Markers




CD138 + - - +
CD56 +/−(usually
-)
Rare + Rare + Ra
Ki67 High >70 % High >90 % High <90 % Hi
Other BLIMP1+ CD10 + BCL-6 Usually + CD
+
CRAB: hypercalcemia, kidney disease, anemia, and bone lytic lesionsSimilar to previously reported studies, the main differ-
ential diagnosis in our study was plasmablastic PCM
particularly if extramedullary. Even though it is difficult,
it is clinically important and critical to differentiate
between these two entities, as treatment for the two-
diseases is significantly different [21].
In practice, morphologic distinction is not always
possible. PBL, particularly when associated with para-
proteinemia and bone lesions, (as in case 1, 3 and 4)
is very difficult to distinguish from PCM with trans-
formation. The designation of these neoplasms is
based mainly on clinical presentation like de novo
presentation as aggressive tumors with plasmablastic
morphology, predominantly extramedullary, often with
mucosal involvement, and associated with HIV and
EBV. These characteristics favor PBL. PCM rarely
present de novo as high-grade lesions and the associ-
ation with EBV and HIV, although previously reported,
remains quite rare [51, 52]. Recently, an immunohisto-
chemistry stain for BLIMP1 and XBP1; markers of ter-
minal B-cell differentiation have been proposed to
identify PBL; however, this finding remains investiga-
tional [53] and these markers are often not routinely
available. There is some controversy whether PCM and
PBL represent two separate entities or are part of a
common pathway. Moreover, Qing and colleagues re-
ported a case where PBL occurred as a result of trans-
formation from a plasmacytoma [54]. However, the
distinction between the two has important clinical and
therapeutic implications.otyping
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PBL has a predilection for immunocompromised individ-
uals based on its prevalence in both HIV-positive patients
and in those undergoing solid organ transplantation. PBL
may be poorly recognized by pathologists, which is partly
attributable to its relatively rare occurrence and unusual
immunophenotype. Morphologically and genomically
speaking, PBL is best classified as a form of DLBCL.
However, based on immunohistochemical data, PBL is
much more similar to an extramedullary PCM. Clinically, it
has a predilection for oral cavity involvement, a feature not
typically seen in other lymphoid malignancies. Recent
studies have shown a high prevalence of MYC
translocations that may contribute to its aggressive nature.
The pathogenesis has not been clearly defined but is
thought to involve dysregulation of terminal B-cell differen-
tiation and apoptosis, potentially due to the effects of MYC
translocation and EBV infection. PBL is a therapeutic chal-
lenge with a clinical course characterized by a high rate of
relapse and death. Overall, PBL is associated with early dis-
semination, poor response to therapy, and limited sur-
vival. To date, treatment responses are usually partial
and temporary. Treatment has been centered on
CHOP chemotherapy with a good initial response;
however, due to a poor survival rate, more intensive
therapies than CHOP or CHOP-like have been rec-
ommended but do not seem to prolong survival. Re-
cent case reports a good clinical response to
bortezomib which is encouraging and may provide
clues to the underlying pathophysiology of PBL. Fi-
nally, it is worthwhile to highlight that no prospective
therapeutic trials have been done specifically in pa-
tients with PBL. In order to improve therapies, fur-
ther research is needed to understand the biology and
molecular pathogenesis of PBL, which seems to be
very heterogeneous. To date, the survival outcome for
PBL remains very poor regardless of intervention.Abbreviations
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